Anika Therapeutics Inc.
ANIK Healthcare Drug Manufacturers Specialty & Generic
Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ANIK
Anika Therapeutics Inc. (ANIK) P/E ratio
Anika Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 126× (January 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 124× | — |
| FY2020 | 0.0× | — |
| FY2019 | 26.9× | 3.91% |
| FY2018 | 25.9× | 2.64% |
| FY2017 | 25.2× | 11.59% |
| FY2016 | 22.6× | 21.85% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| SIGA Siga Technologies Inc. compare | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| BIOA BioAge Labs, Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| LFCR Lifecore Biomedical, Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)